In this study, we aimed to test the effects of MCC950, a specific NLRP3 inhibitor, on the prevention of vincristine‐induced adverse effects as well as tumor progression and vincristine efficacy in NOD/SCID/interleukin‐2 receptor γ‐negative mice patient‐derived xenografts of ALL. This evidence concerns the gene NLRP3 and acute lymphoblastic leukemia.